OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
Powered by tech company’s platform that strives to accelerate clinical development, commercialization of new therapies
Syneos Health, a biopharma clinical and commercial solutions organization, is expanding its partnership with Datavant, who assists organizations with securely connecting health data. The increasing collaboration between the parties, they say, will further leverage the capabilities in Datavant Switchboard—the company’s branded healthcare data platform—and Datavant’s large data ecosystem to accelerate the clinical development and commercialization of new therapies for patients.
Via this expanded relationship, Syneos Health will use Datavant’s tech to develop advanced analytics and AI-driven technologies to execute more efficient clinical trials, creating an improved experience for patients, sites, and biopharma customers. Additionally, the relationship empowers health economics and outcomes research (HEOR), medical affairs, market access, and commercialization analytics and insights to drive better analysis for Syneos Health’s biopharma customers’ products. It also brings to light the importance of evidence continuity across numerous sources, including real-world data (RWD).
“Our continuous collaboration with Datavant will deliver to our customers an established clinical trial tokenization capability and the ability for our teams to leverage this approach to develop new, innovative solutions for conducting clinical research and driving product commercialization that is powered by data-driven insights,” said Bob Zambon, Vice President, Solution Design, Syneos Health. “We’re excited by the opportunity to further utilize the growing suite of capabilities in Datavant Switchboard to support our clients and sites in accelerating and diversifying their clinical trials.”